TGTG Therapeutics TGTX · NASDAQ
$53.97 -3.63% (-$2.03)
- Market cap
- $8.26B
- Enterprise value
- $8.53B
- P/E
- 18.7x
- Forward P/E
- 54.9x
- PEG
- 0.0x
- P/S
- 10.3x
- P/FCF
- -
- EV/EBITDA
- 63.6x
- ROIC
- 43.1%
- Gross margin
- 82.4%
- Net margin
- 55.2%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 2.0x
- Beta
- 1.80
- Free float
- 88.3%
About the company
TG Therapeutics, Inc. (TGTX) is a biotechnology company specializing in the development of therapeutic products in the fields of oncology and autoimmune diseases. The company focuses on discovering and developing innovative treatment approaches that could improve the quality of life for patients suffering from these diseases. TG Therapeutics, Inc. (TGTX) shares may be suitable for investors seeking opportunities in the biotechnology sector and keeping an eye on advancements in the treatment of oncological and autoimmune diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Michael S. Weiss
Employees
399
Headquarters
Morrisville
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number